$429 Million is the total value of Eagle Health Investments LP's 28 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 57.1% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
AZN | Sell | ASTRAZENECA PLCsponsored adr | $25,309,000 | -14.4% | 383,065 | -14.0% | 5.90% | -19.0% |
ARGX | Sell | ARGENX SEsponsored adr | $22,846,000 | +3.7% | 60,300 | -13.7% | 5.33% | -1.9% |
AMWL | Sell | AMERICAN WELL CORPcl a | $16,163,000 | +0.7% | 3,741,413 | -1.8% | 3.77% | -4.7% |
CCCC | Exit | C4 THERAPEUTICS INC | $0 | – | -47,200 | -100.0% | -0.28% | – |
KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -37,000 | -100.0% | -0.39% | – |
MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -52,000 | -100.0% | -1.05% | – |
VRTX | Exit | VERTEX PHARMACEUTICALS INC | $0 | – | -82,144 | -100.0% | -5.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-11
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
IQVIA HLDGS INC | 12 | Q3 2023 | 9.6% |
UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 8.7% |
ALNYLAM PHARMACEUTICALS INC | 12 | Q3 2023 | 8.5% |
NATERA INC | 12 | Q3 2023 | 8.5% |
ARGENX SE | 12 | Q3 2023 | 7.0% |
DEXCOM INC | 12 | Q3 2023 | 5.7% |
OUTSET MED INC | 12 | Q3 2023 | 7.3% |
AGIOS PHARMACEUTICALS INC | 12 | Q3 2023 | 7.2% |
ADAPTIVE BIOTECHNOLOGIES COR | 12 | Q3 2023 | 5.1% |
GUARDANT HEALTH INC | 12 | Q3 2023 | 3.8% |
View Eagle Health Investments LP's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-14 |
13F-HR | 2024-02-12 |
13F-HR | 2023-10-27 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-12 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
13F-HR | 2022-05-12 |
13F-HR | 2022-02-10 |
View Eagle Health Investments LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.